TriGemX Bio and SPAC TCGX Acquisition Corp. announced the confidential submission of a draft S-4 registration statement to the SEC, a milestone toward their proposed merger. The combined company would list on Nasdaq as TGEM. TriGemX's lead candidate elismetrep (migraine) is in Phase 3 with data expected mid-2027. Closing is targeted for Q1 2027, subject to shareholder and regulatory approvals.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
